Elevance Health, Inc.
ELVNYSEHospital & Medical Service PlansFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 21, 2026Score 15/3014% below fair value
$413.60−6.47 (-1.54%)
Close on Nov 2, 2026Market cap $89.70BP/E 18.4Yield –
Elevance Health CarelonRx Segment — GAAP Operating Gain by Year
CarelonRx Segment — GAAP Operating Gain ($M)
Elevance Health CarelonRx Segment — GAAP Operating Gain: $2,418M in FY2025, up 11.3% from a year earlier.
Latest, FY2025
2,418
Period ended Dec 31, 2025
Change on a year earlier
+11.3%
2,172 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| CarelonRx 3 | 724 | 533 | 35.8 | % | 2,418 | 2,172 | 11.3 | %”
Source: 8-K ER (FY2025Q4, 2026-01-28) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CarelonRx Segment — GAAP Operating Gain ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,418 | +11.3% | 8-K ER (FY2025Q4, 2026-01-28) ↗ |
| FY2024 | Dec 31, 2024 | 2,172 | +10.0% | 8-K ER (FY2025Q4, 2026-01-28) ↗ |
| FY2023 | Dec 31, 2023 | 1,975 | +5.7% | 8-K ER (FY2024Q4, 2025-01-23) ↗ |
| FY2022 | Dec 31, 2022 | 1,868 | +10.9% | 8-K ER (FY2022Q4, 2023-01-25) ↗ |
| FY2021 | Dec 31, 2021 | 1,684 | +23.7% | 8-K ER (FY2022Q4, 2023-01-25) ↗ |
| FY2020 | Dec 31, 2020 | 1,361 | – | 8-K ER (FY2021Q4, 2022-01-26) ↗ |
Breakdown
What makes up carelonRx Segment — GAAP Operating Gain
Cite this data
StockData. (2026). Elevance Health CarelonRx Segment — GAAP Operating Gain ($M), annual FY2020–FY2025 [Data set]. Compiled from Elevance Health SEC filings and investor materials. https://stockdatahq.com/stocks/elv/kpis/seg-op-gain-carelonrx
See every metric in the Elevance Health KPI table. Data updated Oct 28, 2026.